
News|Articles|April 11, 2024
Developing & Manufacturing Drugs with HPAPIs
Author(s)Catalent
Developing and manufacturing complex novel oral solid dose products of highly potent compounds requires specialized expertise. The level of containment necessary for a potent drug product is not just limited to potent or non-potent classification. The degree of potency and specific risks will determine the level of containment needed to ensure operator safety and prevent cross contamination at the development and manufacturing facility. This article discusses how to effectively classify highly potent APIs (HPAPIs), and to help develop containment protocols and manufacturing processes that are both safe and efficient.
Trending on Pharmaceutical Technology
1
European Regulators Prepare the Pharma Industry for Future Changes as Legislation is Formalized
2
Assessment of Silicone Oil Cleaning on Indirect Surfaces in Aseptic Manufacturing
3
Technology Transfer: Success Drivers and Obstacles Explained
4
Why Oral Solid Dosage Validation Is a Business Continuity Function, Not Just a Compliance Requirement
5
